Works matching AU Dagogo-Jack, Samuel

Results: 107
    1
    2
    3
    4
    5
    6

    A Polygenic Lipodystrophy Genetic Risk Score Characterizes Risk Independent of BMI in the Diabetes Prevention Program.

    Published in:
    Journal of the Endocrine Society, 2019, v. 3, n. 9, p. 1663, doi. 10.1210/js.2019-00069
    By:
    • Srinivasan, Shylaja;
    • Jablonski, Kathleen A;
    • Knowler, William C;
    • Dagogo-Jack, Samuel;
    • Kahn, Steven E.;
    • Boyko, Edward J;
    • Bray, George A;
    • Horton, Edward S;
    • Hivert, Marie-France;
    • Goldberg, Ronald;
    • Chen, Ling;
    • Mercader, Josep;
    • Harden, Maegan;
    • Florez, Jose C;
    • Group, Diabetes Prevention Program Research
    Publication type:
    Article
    7
    8
    9
    10
    11
    12

    Serum urate and cardiovascular events in the DCCT/EDIC study.

    Published in:
    Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-90785-4
    By:
    • Jenkins, Alicia J.;
    • Braffett, Barbara H.;
    • Basu, Arpita;
    • Bebu, Ionut;
    • Dagogo-Jack, Samuel;
    • Orchard, Trevor J.;
    • Wallia, Amisha;
    • Lopes-Virella, Maria F.;
    • Garvey, W. Timothy;
    • Lachin, John M.;
    • Lyons, Timothy J.;
    • the DCCT/EDIC Research Group;
    • Study Chairpersons;
    • Nathan, D. M.;
    • Zinman, B.;
    • Past;
    • Crofford, O.;
    • Deceased;
    • Genuth, S.;
    • Editor, EDIC Publications
    Publication type:
    Article
    13
    14
    15
    16

    Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
    By:
    • Kim, Joseph M.;
    • Bhatt, Deepak L.;
    • Dagogo‐Jack, Samuel;
    • Cherney, David Z. I.;
    • Cosentino, Francesco;
    • McGuire, Darren K.;
    • Pratley, Richard E.;
    • Liu, Chih‐Chin;
    • Cater, Nilo B.;
    • Frederich, Robert;
    • Mancuso, James P.;
    • Cannon, Christopher P.
    Publication type:
    Article
    17

    Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 758, doi. 10.1111/dom.14923
    By:
    • Corbin, Karen D.;
    • Dagogo‐Jack, Samuel;
    • Cannon, Christopher P.;
    • Cherney, David Z.I.;
    • Cosentino, Francesco;
    • Frederich, Robert;
    • Liu, Jie;
    • Pong, Annpey;
    • Lin, Jianxin;
    • Cater, Nilo B.;
    • Pratley, Richard E.
    Publication type:
    Article
    18

    Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
    By:
    • Segar, Matthew W.;
    • Kolkailah, Ahmed A.;
    • Frederich, Robert;
    • Pong, Annpey;
    • Cannon, Christopher P.;
    • Cosentino, Francesco;
    • Dagogo‐Jack, Samuel;
    • McGuire, Darren K.;
    • Pratley, Richard E.;
    • Liu, Chih‐Chin;
    • Maldonado, Mario;
    • Liu, Jie;
    • Cater, Nilo B.;
    • Pandey, Ambarish;
    • Cherney, David Z. I.
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50